GlassScriptPhysician profile
Betty Tello
NPI 1033892823
$5,264.11
in general payments reported to CMS, 2019-2025
29 companies · $2,030 in 2025
The $2,030 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,057 · 2024: $2,178 · 2025: $2,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,264.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $941.08 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $595.94 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $472.60 | 2024-2025 | Rexulti, Vyepti |
| Pfizer INC. | $470.82 | 2024-2025 | |
| Axsome Therapeutics, INC. | $324.32 | 2023-2025 | Auvelity, Symbravo |
| Teva Pharmaceuticals USA, INC. | $273.54 | 2024-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $221.89 | 2023-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $217.31 | 2023-2025 | Ingrezza |
| Emd Serono, INC. | $196.85 | 2024-2025 | Mavenclad |
| Amneal Pharmaceuticals LLC | $186.14 | 2024-2025 | Crexont, Rytary |
| Microtransponder, INC. | $167.11 | 2025 | |
| Ucb, INC. | $163.77 | 2024-2025 | Nayzilam, Briviact, Rystiggo |
| Janssen Pharmaceuticals, INC | $153.96 | 2023 | Spravato |
| Corium, LLC | $128.40 | 2023-2024 | Azstarys |
| Sk Life Science, INC. | $98.73 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $80.53 | 2024 | Hyqvia |
| Acadia Pharmaceuticals INC | $72.05 | 2024-2025 | Nuplazid, Daybue |
| Merz Pharmaceuticals, LLC | $66.82 | 2024-2025 | Xeomin |
| Supernus Pharmaceuticals, INC. | $58.40 | 2023-2024 | Qelbree, Qelbree |
| Alkermes, INC. | $54.23 | 2024 | Lybalvi |
| Scilex Pharmaceuticals INC. | $53.51 | 2024 | |
| Eisai INC. | $50.12 | 2024 | |
| Vanda Pharmaceuticals INC. | $46.35 | 2024-2025 | Ponvory |
| Lilly USA, LLC | $40.73 | 2024 | Emgality |
| Alexion Pharmaceuticals, INC. | $34.14 | 2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $31.05 | 2024 | Zeposia |
| Hyperfine Operations, INC. | $26.37 | 2025 | Swoop |
| Impel Pharmaceuticals LLC | $19.64 | 2025 | Trudhesa |
| Idorsia Pharmaceuticals US INC | $17.71 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betty Tello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.